Table 6 Comparison of clinical and demographic characteristics between antifibrotic drug-treated group and non-treated group in JRS stage I with GAP stage II/III
From: Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Non-treated group | Treated group | P value | |
|---|---|---|---|
Age, years | 72.2 ± 5.4 | 73.2 ± 7.1 | 0.55 |
Sex, male/female | 29/3 | 34/5 | 0.72 |
Smoking history, N/F/C | 5/23/4 | 4/30/5 | 0.79 |
GAP staging (I/II/III) | 0/27/5 | 0/32/7 | 0.62 |
PaO2, Torr | 88.1 ± 9.8 | 87.9 ± 7.7 | 0.91 |
%FVC, % | 68.2 ± 15.8 | 62.9 ± 13.5 | 0.13 |
%DLco, % | 54.8 ± 21.2 | 55.0 ± 15.2 | 0.95 |
KL-6, U/ml | 971 ± 660 | 1108 ± 699 | 0.40 |
SP-D, ng/ml | 308 ± 291 | 348 ± 297 | 0.57 |
6MWD, m | 351 ± 89 | 349 ± 101 | 0.92 |
Lowest SpO2 on 6MWT, % | 89.4 ± 4.0 | 89.0 ± 5.4 | 0.76 |